High Fragmentation Characterizes Tumour-Derived Circulating DNA
Author Information
Author(s): Florent Mouliere, Bruno Robert, Erika Arnau Peyrotte, Maguy Del Rio, Marc Ychou, Franck Molina, Celine Gongora, Alain R. Thierry
Primary Institution: SysDiag UMR3145 – CNRS, National Centre of the Scientific Research/BIO-RAD, Montpellier, France
Hypothesis
The study investigates the size distribution and fragmentation of circulating tumor DNA (ctDNA) in colorectal cancer patients and its correlation with tumor weight.
Conclusion
Tumor-derived ctDNA fragmentation is significantly higher in metastatic colorectal cancer patients compared to healthy individuals.
Supporting Evidence
- Metastatic colorectal cancer patients showed nearly 5-fold higher mean ctDNA fragmentation than healthy individuals.
- ctDNA quantification by Q-PCR is optimal for 60–100 bp fragments.
- Fragmentation and concentration of tumor-derived ctDNA is positively correlated with tumor weight.
Takeaway
This study found that cancer patients have more broken pieces of DNA in their blood than healthy people, which can help doctors understand the cancer better.
Methodology
The study used a Q-PCR assay to analyze ctDNA size distribution in plasma samples from xenografted mice and metastatic colorectal cancer patients.
Potential Biases
Potential biases may arise from the selection of patient samples and the specific methodologies used for ctDNA analysis.
Limitations
The study primarily focused on a specific patient group (untreated metastatic colorectal cancer patients) and may not generalize to other cancer types or treatment stages.
Participant Demographics
The study included 12 metastatic colorectal cancer patients and 16 healthy individuals.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website